LawFlash

Unified Patent Court Considers the ‘Divisional Game’ in Sandoz v Novo Nordisk

November 16, 2026
10 minute read

Key Takeaways

  • In Sandoz v Novo Nordisk, the Unified Patent Court held that its jurisdiction extends to measures to prevent parties from circumventing its authority, including through the abusive use of divisional patent applications.
  • These measures potentially include (1) declining to terminate proceedings on a patent that has been withdrawn by the patent proprietor to avoid a negative decision on its validity while pursuing equivalent subject-matter in a divisional patent and (2) restraining a party from withdrawing its approval of the text of a patent before the European Patent Office, subject to supporting facts.
  • However, the court rejected Sandoz’s request for an abstract declaration of obviousness. The court held that a declaration directed to the patentability of subject matter, rather than an identified patent, patent claim, patent application, or product, fell outside its competence.
The Unified Patent Court’s (UPC’s) Central Division in Milan issued a procedural order on 22 October 2026 in Sandoz AG v Novo Nordisk A/S (UPC_CFI_2221/2026), a dispute concerning a patent for a composition comprising semaglutide for use in the prevention or treatment of type 2 diabetes. The court rejected Sandoz’s request for an abstract declaration of obviousness but held that it has jurisdiction to grant relief to prevent pending revocation actions from being rendered ineffective through patent withdrawal or related divisional filing strategies. The order provides an important indication of the UPC’s willingness to protect the integrity of its proceedings.

The dispute concerns Novo Nordisk’s Unitary Patent EP 3 689 365, relating to a semaglutide composition for treating type 2 diabetes, administered once weekly at a dose of 1.0 mg with parenteral administration. Sandoz brought revocation proceedings before the UPC’s Central Division in Milan, seeking to revoke the patent in its entirety, principally on grounds of lack of inventive step and added matter.

The challenged patent forms part of a wider patent family that includes a further divisional application, EP 4 406 593, which was pending at the time of the order. While divisional applications serve legitimate purposes, such as addressing lack of unity objections or protecting distinct aspects of an invention, their strategic use can give rise to what Sandoz described as the “divisional game”. This involves pursuing successive divisional applications covering similar subject matter while withdrawing challenged patents before an adverse validity ruling is made, thereby avoiding a determination on validity while substantially similar subject matter remains pending. Such a strategy can create ongoing uncertainty for generic manufacturers, potentially delaying market entry and leaving them facing repeated rounds of patent litigation.

Sandoz therefore sought the following three additional forms of relief aimed at preventing its pending revocation action from being frustrated by the alleged “divisional game”:

  • Request 5 – Declaration of obviousness: A declaration that a semaglutide composition administered subcutaneously once weekly at a dose of 1.0 mg for treating or preventing type 2 diabetes was obvious at the relevant priority date.
  • Request 6 – Declaration concerning substantially similar patent claims: A declaration that claims in Unitary Patents or European Patents within the UPC’s competence, entitled to claim a priority date from the EP 3 689 365 family and broad enough to cover the subject matter of claims 1–5 of the challenged patent, would be invalid for lack of inventive step.
  • Request 7 – Order preventing withdrawal of patent text: An order restraining Novo Nordisk from withdrawing approval of the patent text before the European Patent Office (EPO) under Article 113(2) EPC until a final validity decision by the EPO or UPC.

Novo Nordisk filed a preliminary objection that challenged the UPC’s jurisdiction to consider Requests 5–7. The court addressed those objections in its 22 October order.

THE LIMITS OF BROAD ARROW-TYPE RELIEF

The court upheld Novo Nordisk’s preliminary objection to Request 5, holding that it lacked competence to grant the abstract declaration of obviousness sought and declaring the request inadmissible in its present form.

The court distinguished Request 5 from conventional “Arrow” declarations,[1] which the court stated concern whether an identified product, process, or commercial activity was known or obvious at a relevant date. It noted that Request 5 was “not framed by reference to a specifically identified Sandoz product, process, intended act or market activity”. Instead, Sandoz characterised the request as being directed to the patentability of subject matter, rather than product characteristics, and as intended to bind future divisional patents. On that basis, the court concluded that Request 5 was not a conventional Arrow declaration. The court also expressed concern that such a broadly framed declaration could affect the rights of third parties who were not parties to the proceedings and had no opportunity to be heard.

REVOCATION PROCEEDINGS MAY BE ABLE TO CONTINUE DESPITE PATENT WITHDRAWAL

Request 6 was interpreted by the court as seeking a narrower form of Arrow-type relief designed to preserve the effectiveness of the pending revocation action in circumstances where Novo Nordisk might withdraw the challenged patent so as to avoid a decision on validity while continuing to pursue equivalent subject matter through related divisional patents or applications.

The court held that it had jurisdiction to consider the request, finding in particular that the withdrawal of a challenged patent did not mean the court “automatically loses jurisdiction over the pending action”.[2] Instead, before disposing of the action, the court will hear the parties to assess whether the challenger retains a “concrete and continuing interest” in obtaining a determination of validity. If the evidence establishes that the patentee has pursued a divisional strategy liable to frustrate the pending revocation action, the court reserves the power to decline to dispose of the action under Rule 360 of the Rules of Procedure of the UPC.

The court further confirmed that a determination in these circumstances would not have a direct impact on the validity of divisional patents (covering substantially the same subject matter) yet to be granted. Instead, the earlier determination would become relevant only in the context of the divisional patent’s enforcement or subsequent revocation action. Therefore, any consequences would not be automatic—the court would need to determine, in the light of the circumstances of the case, whether the divisional had, in fact, been employed as an instrument for circumventing the earlier validity determination, and to what extent the claims reproduce or substantially correspond to the subject-matter already adjudicated.

WHEN DOES LEGITIMATE PATENT WITHDRAWAL BECOME PROCEDURAL ABUSE?

The order raises an important question about where to draw the line between legitimate patent portfolio management and the use of procedural rights in a manner that frustrates pending validity challenges. In particular, can those rights be exercised in circumstances that deprive claimants of a meaningful opportunity to obtain a determination on validity while substantially equivalent subject matter continues to be pursued through related divisional patents or applications?

The court found that the existence of a pending divisional application and Novo Nordisk’s reservation of its right to file further divisional applications were insufficient, without more, to establish misconduct at this stage. However, the order leaves open what additional circumstances might justify continued scrutiny of validity notwithstanding withdrawal of the challenged patent.

It is not apparent from the order whether the court’s assessment will focus primarily on the patentee’s intentions, the practical effect of its conduct, or a combination of both. For example, withdrawing a patent after receiving an adverse preliminary assessment may reflect a legitimate reassessment of litigation risk. Equally, withdrawal shortly before a validity determination, coupled with the continued pursuit of substantially equivalent subject matter through divisional filings, may raise different considerations. The evidential threshold required to demonstrate procedural abuse is therefore likely to be an important issue in future cases.

CAN THE UPC RESTRICT A PATENTEE’S CONDUCT BEFORE THE EPO?

The court dismissed Novo Nordisk’s preliminary objection to Request 7, holding that it has the jurisdiction and power to order measures restraining a patentee from withdrawing approval of the patent text before the EPO under Article 113(2) EPC, where necessary to preserve the revocation proceedings. However, the UPC declined to decide whether such relief should be granted in this case because the request was not supported by specific factual circumstances. Instead, it will consider the merits of the request (including urgency, necessity, proportionality, and the appropriate scope of any measure) only if the request is reformulated and supported by “concrete facts”.

An interesting aspect of the order is the basis on which the court considered it could grant relief affecting a party’s conduct before the EPO. The court maintained that it could prevent an abuse of rights (the right to file a divisional) when those rights are used for a different purpose to that for which the right was conferred. It held that circumventing effective judicial determination of patent validity (if proved) was not the purpose for which the right to file a divisional was granted.

Although this case was the first of its kind before the UPC, a similar injunction was issued by the Munich I District Court in 2020 against Teva, limiting its ability to withdraw approval of the text of a patent covering its Copaxone product. In that case, the injunction was based on an alleged breach of the German Unfair Competition Act and the alleged intended exclusion of competitors from the market. Such a distinction could, if the UPC decision is upheld on appeal, broaden the circumstances in which a challenger can obtain anti-divisional-game relief to those which do not involve threatened exclusionary relief based on the patent. It also aligns the basis of such relief more closely to the explicit competencies of the UPC compared to national courts.

IMPLICATIONS

  • Patentees should assess withdrawal and divisional filing strategies where related family members remain pending. Withdrawal of a challenged patent may not prevent the UPC from determining validity, reducing the ability of patentees to avoid a validity ruling while continuing to pursue substantially similar subject matter through related family members.
  • A validity determination may not eliminate uncertainty across the wider patent family. Although the court was prepared to consider relief directed at substantially equivalent subject matter pursued through related divisional patents and applications, the effect of any future ruling on those family members remains to be determined. Continued patent family monitoring and claim-specific freedom-to-operate assessments will remain important.
  • Steps taken before the EPO may become increasingly relevant to UPC litigation strategy. The court held that it has competence to consider measures preventing withdrawal of approval of the patent text where necessary to preserve pending revocation proceedings, potentially limiting a patentee’s procedural options before the EPO. This may be a collateral benefit of bringing revocation actions before the UPC where there are pending divisionals and EPO opposition proceedings.

WHAT COMES NEXT

Although the court rejected Sandoz’s request for an abstract declaration of obviousness, it confirmed its jurisdiction to hear Requests 6 and 7. The main proceedings are expected to address the scope and merits of Request 6, as well as whether the measures sought under Request 7 are justified.

The court’s approach to those issues may provide important guidance on the boundary between legitimate patent portfolio management and procedural abuse, and on the extent to which the UPC is willing to intervene to prevent the alleged “divisional game” from frustrating pending revocation actions. The court also granted permission to appeal the order, meaning that we may receive early guidance from the UPC Court of Appeal on these issues. For now, the UPC is aligning with the existing approach of some national courts in entertaining Arrow-type declaratory relief.



Authors

パートナー
パートナー
アソシエイト
アソシエイト

[1] Named after the UK case that first established the availability of such relief.

[2] Rule 360 of the UPC Rules of Procedure permits the court to dispose of an action where it finds that the action has become devoid of purpose and there is no longer a need to adjudicate.